Overall, DNAM-1+ GM NK-92 cells exerted increased cytotoxic activity compared to WT controls in the imaging-based assays, supporting the degranulation results obtained and putting forward DNAM-1 as a prominent candidate in sarcoma immunotherapy. The gene discussed is CD226; the disease is sarcoma.